Ahmed Alkhiri

Ahmed Alkhiri

Auto-generated profile, based on publicly available information

Ahmed Alkhiri

College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
FAFahad S. Al‐Ajlan
Fahad S. Al‐Ajlan
AAAhmed Alkhiri
Ahmed Alkhiri
AAAser F. Alamri
Aser F. Alamri
BABasil A. Alghamdi
Basil A. Alghamdi
AAAhmed A. Almaghrabi
Ahmed A. Almaghrabi
AAAdel Alhazzani
Adel Alhazzani
Objectives: The benefits of intravenous thrombolysis are time‐dependent, with maximum efficacy when administered within the first “golden” hour after onset. Nevertheless, the impact of golden hour thrombolysis has not been well quantified.Methods: Medline, Embase, and Web of Science databases were systematically searched from inception to August 27, 2023. We included studies that reported safety and efficacy outcomes of ischemic stroke patients treated with intravenous thrombolysis in the golden hour versus later treatment window. The primary outcome was an excellent functional outcome, defined as a modified Rankin Scale score of 0–1 at 90 days. The secondary efficacy outcome was a good functional outcome (defined as modified Rankin Scale score of 0–2). The main safety outcome was symptomatic intracerebral hemorrhage.Results: Seven studies involving 78,826 patients met the selection criteria. Golden hour thrombolysis was associated with higher odds of 90‐day excellent functional outcomes (OR 1.40, 95% CI 1.16–1.67) and 90‐day good functional outcomes (OR 1.38, 95% CI 1.13–1.69) compared with thrombolysis outside the golden hour. The number needed to treat to benefit for golden hour thrombolysis to reduce disability by at least 1 level on the modified Rankin Scale per patient was 2.6. Rates of symptomatic intracerebral hemorrhage and mortality were similar between groups.Interpretation: Golden hour thrombolysis significantly improved acute ischemic stroke outcomes. The findings provide rationale for intensive efforts aimed at expediting thrombolytic therapy within the golden hour window following the onset of acute ischemic stroke. ANN NEUROL 2024;96:582–590

1 September 2024 in European Stroke Journal
Verified
Journal Article
Closed access
AAADEL ALHAZZANI
ADEL ALHAZZANI
FAFahad S Al-Ajlan
Fahad S Al-Ajlan
AAAhmed Alkhiri
Ahmed Alkhiri
AAAhmed A Almaghrabi
Ahmed A Almaghrabi
AAAser F Alamri
Aser F Alamri
Thanh N NguyenThanh N Nguyen
Thanh N Nguyen
Background: Minor ischemic stroke, defined as National Institute of Health Stroke Scale score of 0–5 on admission, represents half of all acute ischemic strokes. The role of intravenous alteplase (IVA) among patients with minor stroke is inconclusive; therefore, we evaluated clinical outcomes of these patients treated with or without IVA. Materials and methods: We searched Medline, Embase, Scopus, and the Cochrane library until August 1, 2023. Inclusion was restricted to the English literature of studies that reported on minor nondisabling stroke patients treated with or without IVA. Odds ratios (ORs) with their corresponding 95% CIs were utilized using a random-effects model. Efficacy outcomes included rates of excellent (modified Rankin scale [mRS] of 0–1) and good (mRS of 0–2) functional outcome at 90 days. The main safety outcome was symptomatic intracerebral hemorrhage (sICH). Results: Five eligible studies, two RCTs and three observational studies, comprising 2764 patients (31.8% female) met inclusion criteria. IVA was administered to 1559 (56.4%) patients. Pooled analysis of the two RCTs revealed no difference between the two groups in terms of 90-days excellent functional outcomes (OR 0.76 [95% CI, 0.51–1.13]; I 2 = 0%) and sICH rates (OR 3.76 [95% CI, 0.61–23.20]). No significant differences were observed between the groups in terms of good functional outcomes, 90-day mortality, and 90-day stroke recurrence. Conclusion: This meta-analysis of minor nondisabling stroke suggests that IVA did not prove more beneficial compared to no-IVA.

1 March 2024 in European Stroke Journal
Verified
Journal Article
Closed access
AAAhmed Alkhiri
Ahmed Alkhiri
AAAser F Alamri
Aser F Alamri
AAAbdullah R Alharbi
Abdullah R Alharbi
AAAhmed A Almaghrabi
Ahmed A Almaghrabi
NANayef Alansari
Nayef Alansari
FAFahad S Al-Ajlan
Fahad S Al-Ajlan
Background and purpose: Isolated posterior cerebral artery occlusions (iPCAO) were underrepresented in pivotal randomized clinical trial (RCTs) of endovascular thrombectomy (EVT) in ischemic stroke, and the benefit of EVT in this population is still indeterminate. We performed a systematic review and a meta-analysis to compare the safety and efficacy of EVT compared to best medical management (BMM) in patients with iPCAO. Methods: We searched Medline/PubMed, Embase, Web of Science, and the Cochrane databases up to May 2023 for eligible studies reporting outcomes of patients with iPCAO treated with EVT or BMM. We pooled odds ratios (ORs) with corresponding 95% confidence intervals (CI) using a random-effects model. Results: Seven studies involving 2560 patients were included. EVT was associated with significantly higher likelihood of early neurological improvement (OR, 2.31 [95% CI, 1.38–2.91]; p < 0.00001) and visual field normalization (OR, 3.08 [95% CI, 1.76–5.38]; p < 0.0001) compared to BMM. Rates of good functional outcomes (mRS 0–2) were comparable between the two arms (OR, 0.88 [95% CI, 0.70–1.10]; p = 0.26). Symptomatic intracranial hemorrhage (sICH) was comparable between the two groups (OR, 1.94 [95% CI, 0.96–3.93]; p = 0.07). Mortality was also similar between the two groups (OR, 1.36; [95% CI, 0.77–2.42]; p = 0.29). Conclusions: In patients with iPCAO, EVT was associated with visual and early neurological improvement but with a strong trend toward increased sICH. Survival and functional outcomes may be slightly poorer. The role of EVT in iPCAO remains uncertain.

31 October 2024 in Annals of Neurology
Verified
Journal Article
Closed access
AAAhmed Alkhiri
Ahmed Alkhiri
AAAser F. Alamri
Aser F. Alamri
AAAhmed A. Almaghrabi
Ahmed A. Almaghrabi
FAFahad Alturki
Fahad Alturki
BABasil A. Alghamdi
Basil A. Alghamdi
FAFahad S. Al‐Ajlan
Fahad S. Al‐Ajlan

12 June 2025 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
AAAhmed Alkhiri
Ahmed Alkhiri
FAFahad Alturki
Fahad Alturki
AAAser F Alamri
Aser F Alamri
HSHassan K Salamatullah
Hassan K Salamatullah
AAAhmed A Almaghrabi
Ahmed A Almaghrabi
AAADEL ALHAZZANI
ADEL ALHAZZANI
Background Despite high recanalization rates with endovascular thrombectomy (EVT) for large vessel occlusions, functional outcomes remain suboptimal. This study investigates whether adjunctive intra-arterial (IA) thrombolysis following successful EVT can improve patient outcomes. Methods A systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. We searched Medline, Embase, Web of Science, and Cochrane databases. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for functional and safety outcomes. Results Seven trials (2131 patients) were included. IA thrombolysis was administered to 1081 (50.7%) patients. Patients receiving adjunctive IA thrombolysis had higher odds of excellent functional outcomes (modified Rankin Scale (mRS) 0–1) at 90 days (OR 1.44, 95% CI 1.21 to 1.72) compared with the EVT-alone group while maintaining similar rates of symptomatic intracerebral hemorrhage (sICH; OR 1.15, 95% CI 0.75 to 1.75). Subgroup analysis of excellent functional outcomes showed that the benefits of IA thrombolysis were primarily observed in specific patient populations: those treated with alteplase 0.225 mg/kg or tenecteplase 0.125 mg/kg, patients with lower expanded Thrombolysis in Cerebral Infarction (eTICI) scores, higher initial National Institutes of Health Stroke Scale (NIHSS), and those with cardioembolic etiology. Mortality rates and good functional outcomes (mRS 0–2) remained comparable between treatment groups. Conclusion Adjunctive IA thrombolysis following successful EVT may improve functional outcomes without added risk of sICH. Certain patient subgroups (those with lower recanalization rates, higher NIHSS, and cardioembolic etiology) and specific thrombolytic agents and dosages (alteplase 0.225 mg/kg, tenecteplase 0.125 mg/kg) appear to derive greater benefits from this approach. Further research is needed to validate these findings and refine patient selection.

13 January 2025 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
AAAhmed Alkhiri
Ahmed Alkhiri
HAHatoon Alshaikh
Hatoon Alshaikh
MAMohammed S Alqahtani
Mohammed S Alqahtani
SAShatha Alqurashi
Shatha Alqurashi
MAManar M Alsharif
Manar M Alsharif
AAADEL ALHAZZANI
ADEL ALHAZZANI
Background: The periprocedural management of antithrombotic medications in patients with chronic subdural hematoma (cSDH) after middle meningeal artery embolization (MMAE) or surgical evacuation is uncertain. Methods: A systematic review was conducted across Medline, Embase, and Web of Science databases. We pooled proportions and risk ratios (RRs) for the meta-analysis with the corresponding 95% CIs. Systemic and intracranial (including recurrence) bleeding complications and thromboembolic events were evaluated. Results: Of the 16 included studies with 4606 patients, 1784 were receiving antithrombotic medications. Antithrombotic therapy was resumed in 1231 patients (69.0%). Bleeding complications were similar between patients in whom antithrombotic therapy was resumed (14.1%, 95% CI 9.7% to 20.2%) and in those in whom it was discontinued (15.4%, 95% CI 7.4% to 29.3%). After MMAE, patients had similar rates of bleeding events (12.1%, 95% CI 4.9% to 27.0%) to patients with overall treated cSDH, and recurrence (RR 2.28, 95% CI 0.46 to 11.37) and reoperation (RR 1.07, 95% CI 0.40 to 2.917) risks were similar between the resumed and discontinued groups. Thromboembolic complications were significantly higher in the discontinued group (12.6%, 95% CI 6.5% to 23.0%) than in the resumption group (3.5%, 95% CI 1.8% to 6.9%). Earlier resumption (1 week to 1 month) was associated with a lower thromboembolic risk without increasing bleeding complications. Conclusions: Post-procedural antithrombotic resumption may reduce thromboembolic events without significantly increasing bleeding risk. Early resumption of antithrombotics post-MMAE appears to be safe, although further data are required to confirm this observation. Future studies should aim to better define patient characteristics influencing decision-making in this context.